Ariosa Diagnostics, Inc.

Roche Molecular Systems, Inc.

Emc IP Holding Company LLC

Roche Sequencing Solutions, Inc.

Ariosa Diagnosis, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Craig Struble

Arnold Oliphant

Eric Wang

Andrew Sparks

John Stuelpnagel

Christopher Hercules Claudatos

Michael John Dutch

Ken Song

Rachel L Traylor

The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.

Assay systems for genetic analysis

The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.

Risk calculation for evaluation of fetal aneuploidy

The present invention provides methods for non-invasive determination of sex in a fetus or of Y chromosomal frequency abnormalities&#x2014;indicative of aneuploidy or sex mosaicisms in a fetus&#x2014;by detecting and determining the relative contribution genetic sequences from the Y chromosome in view of the percent fetal contribution in a maternal mixed sample.

Non-invasive fetal sex determination

The present invention provides assay systems and methods for determining the percent fetal contribution of cell-free DNA in a maternal sample from a pregnant female with an egg donor pregnancy. Further provided, are assay systems and methods for determining a statistical likelihood of the presence or absence of a fetal aneuploidy in a maternal sample using a determined percent fetal cell-free DNA in the sample.

Noninvasive detection of fetal aneuploidy in egg donor pregnancies

The present invention provides processes for calculating phased genomic sequences of the fetal genome using fetal DNA obtained from a maternal sample. The processes and systems of the present invention utilize novel technological and computational approaches to detect fetal genomic sequences and determine the phased heritable genomic sequences. The invention could be used, e.g., to identify in utero deleterious mutations carried by the parents and inherited by a fetus within a particular heritable genomic region.

Processes for calculating phased fetal genomic sequences

This invention relates to a binomial calculation of copy number of data obtained from a mixed sample having a first source and a second source.

Determination of copy number variations using binomial probability calculations

The present invention provides methods for non-invasive determination of X and/or Y chromosomal abnormalities indicative of aneuploidy or sex mosaicisms in a maternal sample by detecting and determining the relative contribution of genetic sequences from the X chromosome and/or the Y chromosome in the maternal sample.

Statistical analysis for non-invasive sex chromosome aneuploidy determination

The present invention provides processes for determining accurate risk probabilities for chromosome dosage abnormalities. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.

Assay systems for determination of fetal copy number variation

Embodiments are directed to a method and system for allocating common resources for a user in a cloud computer network, by: monitoring system reliability and resource charges; estimating a reliability based on the monitored system reliability and simulating resource provisioning choices to measure an impact of resource provisioning on the estimated reliability; estimating a cost based on the monitored resource charges; and allocating network resources based the estimated cost and simulated resource provisioning choices.

Growing community of inventors

San Jose, CA, United States of America

Craig Struble